Liver cirrhosis
Conditions
Interventions
None listed
Sponsors
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient who is older than 20 when the informed consent is obtained. 2. The patient who was diagnosed with liver cirrhosis and hepatic encephalopathy before the registration. 3. The administration of rifaximin is clinically appropriate. 4. The performance status of the patients is 0, 1, or 2. 5. The patient who is possible to be followed for 4 weeks after the administration of rifaximin. 6. The patient whose informed consent is obtained.
Exclusion criteria
Exclusion criteria: 1. The patient who is pregnant or performing breast feeding. 2. The patient who was registered in this study before. 3. The patient who has allergy to rifaximin. 4. The patient who has colostomy or cannot collect stool correctly. 5. The patient who has severe constipation and a risk for ileus by preparation for cine-MRI. 6. The patient who has contraindications for MRI (i.e. a cardiac pace maker, claustrophobia, metal product in the body, etc.). 7. The patients who are judged by the investigators to be inappropriate participants in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of small intestinal motility before and after administration of rifaximin for 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of microbiota before and after administration of rifaximin for 4 weeks. | — |
Countries
Japan
Contacts
Public ContactKazuya Takahashi
Graduate School of Medical and Dental Sciences, Niigata University Division of Gastroenterology and Hepatology
Outcome results
None listed